No significant relationship exists between tumor size and prognosis in distant metastatic hepatocellular carcinoma: a propensity score matching analysis based on SEER database

Hepatocellular carcinoma (HCC) accounts for 75–85% of primary liver cancer (PLC), and is the main histological type of primary liver cancer [1, 2]. HCC ranks third in cancer-related mortality, causing over 500,000 deaths worldwide annually [3]. The prevalence of HCC is significantly higher in North and West Africa, and East and South-East Asia, and 50% of reported HCC cases originate in China. HCC is associated with poor prognosis, and the incidence of HCC is increasing in many countries [4]. Although hepatectomy provides a chance of cure or a prolonged life expectancy, it is only feasible in 20–40% of patients. Other local treatments, such as radiofrequency ablation, transcatheter arterial chemoembolization, ethanol injection and sorafenib, prolong the lives of patients with resectable tumors [5]. Although progress has been made in the diagnosis and treatment of HCC, the median survival time of patients with HCC is 33 months [6], and the prognosis can still be improved. There are many factors affecting the prognosis of HCC, including portal hypertension, the level of bilirubin, the tumor number and vascular invasion [7]. Therefore, it is critical to determine the prognostic factors related to clinical outcomes.

Many studies have shown that tumor size is a poor prognostic factor for various cancers, such as colon cancer [8‐11], esophageal cancer [12], breast cancer [13, 14] and thyroid cancer [15]. Therefore, many scholars have explored the relationship between tumor size and HCC patient prognosis. However, whether tumor size can be used as an independent factor to predict the prognosis of hepatocellular carcinoma (HCC) patients is still controversial. Some researchers have suggested that tumor size is a prognostic factor in HCC. In most cases, the larger the tumor is, the worse the prognosis will be. Tumor size has been included in most HCC surgical staging systems [16, 17]. However, several large studies [18, 19] subsequently showed that tumor size is not a single independent prognostic factor in HCC, and large hepatocellular carcinoma is associated with poor prognosis because of its association with other adverse prognostic factors, such as vascular invasion, tumors with higher multifocality and tumors of higher, grades. A recent study showed that tumor size at diagnosis can be used as an independent risk predictor of histological grade, staging, surgical choice and survival outcome in HCC patients [20].

In this study, we collected data on HCC patients from the SEER database from 2010 to 2015, and screened the data of advanced liver cancer patients for analysis. The propensity matching score was used to evaluate whether tumor size could be used as an independent prognostic factor to predict the survival outcome of advanced HCC patients.

We used SPSS Statistics version 21.0 (SPSS Inc., Chicago, IL) and the R statistical computing environment (R Foundation for Statistical Computing, Vienna, Austria)) for data analysis. Continuous variables are expressed as the mean and standard deviation, and classified data are expressed as counts and percentages, which are used in survival analysis. The MatchIt package was used to perform PSM, propensity scores estimated with logistic regression. The caliper width is set to 0.1. The standardized mean difference method (SMD) was used to compare the balance between the tumor size ≤ 50 mm group and the tumor size > 50 mm group, with a value greater than 0.10 indicating imbalance [22]. The MBESS package was used to calculate the SMD value. Pearson’s chi-square test was used to compare the baseline characteristics and differences between the two groups. Continuous variables were analyzed by a t-test. The multivariate analysis was performed using the Cox proportional hazard model. Cox regression analysis was used to calculate the hazard ratio (HR) and 95% confidence interval (95% CI).

Clinicopathological characteristics of distant metastatic hepatocellular carcinoma patients.

A total of 804 patients with HCC treated from 2010 to 2015 were divided into two groups with 50 mm as the cut-off point for tumor size. The baseline characteristics of 189 patients with tumor size ≤ 50 mm and 615 patients with tumor size > 50 mm are shown in (Table 1). We selected HCC patients with distant metastasis in stage M1. The average age of patients with tumors ≤ 50 mm was 63.4 years, and the average age of patients with tumors > 50 mm was 64.6 years. We observed that regardless of the size of the tumor, most of the patients with advanced hepatocellular carcinoma were male, and most of them were AFP-positive patients who had not undergone surgery. Both before and after propensity score matching, the tumor size of HCC patients was not related to age, sex, race (American Indian / AK Native, Asian / Pacific Islander), grade, surgical treatment, N, or AFP (p > 0.05). However, before PSM, the SMD values of race、grade、surgical treatment, N and AFP were all greater than 0.1, indicating that these factors had a certain impact on our analysis. Therefore, the PSM method was used to reduce the influence of confounding factors. The propensity scores of hepatocellular carcinoma patients in different groups in the selected SEER database were matched (Fig. 2). After PSM, all of the SMD values were lower than 0.1 (Table 2), indicating that all baseline variables were matched completely among the 186 selected patients with tumors ≤ 50 mm and the 186 matched patients with tumors > 50 mm.

Effect of tumor size on the overall survival (OS) rate of patients with advanced hepatocellular carcinoma.

We performed Kaplan–Meier analysis before and after PSM. The Kaplan–Meier analysis and log-rank test showed that before PSM, the mortality rate of patients with tumor size > 50 mm was significantly higher than that of patients with tumor size ≤ 50 mm (P = 0.00062) (Fig. 3a). Propensity score matching was performed to minimize any deviations resulting from the influence of age, race, sex, surgical treatment, tumor grade, and AFP. After matching all potential confounding factors, there was no significant difference in the survival rate of patients with advanced liver cancer with a tumor size > 50 mm and that of those with a tumor size ≤ 50 mm (P = 0.23) (Fig. 3b).

In this study, we collected and analyzed the SEER database data on 804 patients with type M1 hepatocellular carcinoma. The results showed that the p values of all the influencing factors were below 0.05, but the distance balance distribution curve revealed an imbalance, thus, we used the SMD value for the analysis. We used PSM to exclude all confounding factors, and we observed that all clinical features were matched between the group with tumor sizes ≤ 50 mm and the group with tumor sizes > 50 mm. In addition, we analyzed the survival rates of the two groups before and after matching. The results showed that tumor size could not independently predict the prognosis of M1 hepatocellular carcinoma patients.

The incidence of HCC increasing worldwide. HCC is an invasive malignant tumor and one of the most common causes of cancer-related death. Surgery is the main choice for the treatment of hepatocellular carcinoma and is, most effective treatment, for obtaining the best overall survival rate and recurrence-free survival rate [23]. A considerable proportion of HCC patients present with advanced large hepatocellular carcinoma at the time of the initial diagnosis. When liver function is maintained within an acceptable range, surgical treatment is considered to be the first choice for these large liver cancers [24]. Radiofrequency ablation (RFA) is the preferred treatment for patients who are not eligible for surgery or orthotopic liver transplantation. Postoperative recurrence is closely related to patient survival [25], and angiotensin receptor blockers can improve the survival outcomes of HCC patients after RFA [26]. However, in our study, the vast majority of advanced HCC patients did not receive surgical treatment, and we speculate that some patients may have died before receiving surgery or that their bodies deteriorated to the extent that they were unable to withstand surgical treatment. We also observed that the survival rate of AFP-positive patients was lower than that of AFP-negative patients. This finding is in agreement with the conclusion of a previous study in which it was shown that AFP level is an independent risk factor associated with tumor differentiation, TNM stage, tumor size and survival outcome among in patients with liver cancer. Compared with AFP-negative tumors, AFP-positive tumors had lower differentiation levels [27, 28], were of later TNM stage [29, 30], and patients had larger tumors and lower survival rates [29, 31‐34]. In addition, some comorbidities can also affect the occurrence and prognosis of HCC. For example, due to the prevalence of obesity and type-2 diabetes mellitus, Non Alcoholic Fatty Liver Disease (NAFLD) /is now becoming a major risk factor of HCC, and distant metastasis is more likely to occur in HCC patients complicated with diabetes, thus affecting patient survival [35].

The typical feature of most malignant tumors is growth accompanied by distant organ metastasis, which is the main factor leading to death. Hepatocellular carcinoma most frequently metastasizes to the lungs, followed by the bones and other sites [32‐34]. When distant metastasis occurs, adverse reactions in various tissues and organs of the body aggravate the patient's condition and eventually lead to death. Relatively speaking, the size of the tumor may have little effect on the patient. The purpose of this study was to better understand the effect of tumor size on the prognosis of liver cancer patients with distant metastases. Larger tumors are generally associated with poorer survival outcomes, this may make patients with larger tumors more anxious. Emotions have an impact on survival in patients with advanced cancer [36]. This study may reduce anxiety in some patients with large tumor and provide guidance for clinicians in choosing treatment options. Further understanding of the effect of tumor size on the survival rate of patients with distant metastasis will help to correctly classify advanced HCC patients and may provide a reference for individualized and targeted therapy.